Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Polish Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maramattom, B. V.
Right arrow Articles by Lindell, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maramattom, B. V.
Right arrow Articles by Lindell, E. P.
Related Collections
Right arrow All Imaging
Right arrow All Toxicology
NEUROLOGY 2005;64:1276-1278
© 2005 American Academy of Neurology
Brief Communications

Gadolinium encephalopathy in a patient with renal failure

Boby Varkey Maramattom, MD, DM, Edward M. Manno, MD, Eelco F.M. Wijdicks, MD and Edward P. Lindell, MD

From the Division of Critical Care Neurology, Department of Neurology (Drs. Maramattom, Manno, and Wijdicks), and the Department of Neuroradiology (Dr. Lindell), Mayo Clinic College of Medicine, Rochester, MN.

Address correspondence and reprint requests to Dr. Eelco F.M. Wijdicks, Mayo Clinic College of Medicine, Department of Neurology, W8B, 200 First Street SW, Rochester, MN 55905; e-mail: wijde{at}mayo.edu

Gadolinium chelates are extensively used in MRI studies. Neurotoxicity due to gadolinium chelates is minimal and uncommon. A 57-year-old woman in renal failure developed a subacute encephalopathy after inadvertent repetitive gadolinium contrast administration. An unusual MRI appearance with CSF hyperintensity due to gadolinium diffusion into the CSF is also shown.

Received September 20, 2004. Accepted in final form December 27, 2004.




This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
W.P. Dillon
Intrathecal Gadolinium: Its Time Has Come?
AJNR Am. J. Neuroradiol., January 1, 2008; 29(1): 3 - 4.
[Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
J.M. Morris and G.M. Miller
Increased Signal in the Subarachnoid Space on Fluid-Attenuated Inversion Recovery Imaging Associated with the Clearance Dynamics of Gadolinium Chelate: A Potential Diagnostic Pitfall
AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1964 - 1967.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
L.M. Levy
Exceeding the Limits of the Normal Blood-Brain Barrier: Quo Vadis Gadolinium?
AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1835 - 1836.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.